MMQ0 Stock Chart & Stats
€36.60
€0.60(1.60%)
At close: 4:00 PM EDT
€36.60
€0.60(1.60%)
Day’s Range― - ―
52-Week Range€8.98 - €42.70
Previous CloseN/A
Volume30.00
Average Volume (3M)46.00
Market Cap
€4.27B
Enterprise Value€4.16B
Total Cash (Recent Filing)€1.08B
Total Debt (Recent Filing)€36.47M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 05, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.44
Shares Outstanding134,366,940
10 Day Avg. Volume70
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€64.24Price Target Upside75.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-2.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical ValidationRepeated Phase 3 success materially de-risks DT120’s development program and supports a defined regulatory path. Meeting efficacy endpoints across major indications could improve approval prospects and create a durable commercial opportunity if the planned filing progresses successfully.
FDA Regulatory SupportBreakthrough Therapy designation can strengthen regulatory engagement and highlights DT120’s potential to address a substantial unmet need. Combined with durable Phase 3 efficacy, it may accelerate development and improve the asset’s strategic value over the next several quarters.
Supportive Balance SheetA large equity and asset base alongside modest debt provides meaningful financial capacity for a development-stage biotech. This structure reduces near-term solvency pressure and gives Definium more flexibility to fund clinical, regulatory, and corporate activities.
Bears Say
Pre-revenue Business ModelThe absence of reported revenue means Definium currently depends on financing and successful development rather than recurring operating income. Until a candidate is approved and commercialized, the company has limited internal funding capacity and remains exposed to execution risk.
Widening Operating LossesRapidly widening EBIT and net losses indicate that the cost base is increasing faster than any visible path to revenue. Persistent losses can consume the capital raised for development, reduce financial flexibility, and increase dependence on future funding.
Accelerating Cash BurnHigher absolute cash outflows increase the amount of capital Definium must secure before potential commercialization. Continued burn raises funding and dilution risk, while the lack of operating cash generation leaves the company vulnerable if development timelines or regulatory milestones extend.
Definium Therapeutics News
MMQ0 FAQ
What was Definium Therapeutics’s price range in the past 12 months?
Definium Therapeutics lowest stock price was €8.98 and its highest was €42.70 in the past 12 months.
What is Definium Therapeutics’s market cap?
Definium Therapeutics’s market cap is €4.27B.
When is Definium Therapeutics’s upcoming earnings report date?
Definium Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 28 days.
How were Definium Therapeutics’s earnings last quarter?
Definium Therapeutics released its earnings results on Aug 06, 2026. The company reported -€1.285 earnings per share for the quarter, missing the consensus estimate of -€0.483 by -€0.802.
Is Definium Therapeutics overvalued?
According to Wall Street analysts Definium Therapeutics’s price is currently Undervalued.
Does Definium Therapeutics pay dividends?
Definium Therapeutics does not currently pay dividends.
What is Definium Therapeutics’s EPS estimate?
Definium Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Definium Therapeutics have?
Definium Therapeutics has 134,366,940 shares outstanding.
What happened to Definium Therapeutics’s price movement after its last earnings report?
Definium Therapeutics reported an EPS of -€1.285 in its last earnings report, missing expectations of -€0.483. Following the earnings report the stock price went up 0.771%.
Which hedge fund is a major shareholder of Definium Therapeutics?
Currently, no hedge funds are holding shares in DE:MMQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€64.24 (75.52% Upside)
€64.24 (75.52% Upside)
Blogger Sentiment
Bullish
DE:MMQ0 Sentiment 93%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
193.14%
12-Months-Change
Fundamentals
Return on Equity
-85.23%
Trailing 12-Months
Asset Growth
319.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Definium Therapeutics
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
MMQ0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DE:MMQ0 earnings summariesMMQ0 Stock 12 Month Forecast
Average Price Target
€64.24
▲(75.52% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―